Harvey Hopkins, MD
Pulmonary Disease · Lincoln, NENPI 1871597583
Payments from drug & device makers
What this record shows
This record is dominated by education: $12,122 of the $18,184 with a category attached, or 66.7%. Intuitive Surgical accounts for 69.2% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2023 at $13,824 and has fallen 91.0% since, to $1,251 in 2025. Among pulmonary disease clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 288 payments — averaging $63.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$13K
- Inspire Medical Systems, Inc.$1K
- Jazz Pharmaceuticals Inc.$890
- Harmony Biosciences LLC$495
- Sanofi$361
- AstraZeneca$321
- plus $2K from 27 others
What the payments were for
- Travel & lodging$1,3207%
- Food & beverage$4,74326%
- Education$12,12267%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 12 | $12,590 |
| Inspire Medical Systems, Inc. | 9 | $1,077 |
| Jazz Pharmaceuticals Inc. | 54 | $890 |
| Harmony Biosciences LLC | 41 | $495 |
| Sanofi | 16 | $361 |
| AstraZeneca | 11 | $321 |
| United Therapeutics Corporation | 15 | $310 |
| Boehringer Ingelheim | 15 | $249 |
| Grifols USA, LLC | 11 | $237 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $172 |
| Insmed, Inc. | 16 | $165 |
| Sunovion Pharmaceuticals Inc. | 8 | $163 |
| Electromed, Inc. | 11 | $145 |
| Genentech USA, Inc. | 17 | $130 |
| Mallinckrodt Hospital Products Inc. | 4 | $121 |
| Regeneron Healthcare Solutions, Inc. | 7 | $120 |
| GSK | 6 | $102 |
| Axsome Therapeutics, Inc. | 4 | $67 |
| Tactile Systems Technology Inc | 2 | $64 |
| Philips North America LLC | 3 | $54 |
| Verona Pharma, Inc. | 2 | $50 |
| Resmed Corp | 1 | $48 |
| Mylan Specialty L.p. | 3 | $42 |
| Amgen | 2 | $34 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $33 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $19 |
| Bayer | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Merck | 1 | $14 |
| AbbVie | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$9,226
- ION$3,000
- Inspire$896
How this compares
$18,184 in reported general payments places this provider in the 90th percentile of 81 pulmonary disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 37 | $478,543 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 123 | $96,025 |
| Pirfenidone | 11 | $45,607 |
| Breo ElliptaFluticasone/Vilanterol | 66 | $27,269 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $14,813 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $10,020 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $7,311 |
| Tiotropium Bromide | 11 | $5,037 |
| DuleraMometasone/Formoterol | 12 | $4,016 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 114 | $3,356 |
| BreynaBudesonide/Formoterol Fumarate | 12 | $1,896 |
| Esomeprazole Magnesium | 42 | $1,875 |
| Omeprazole | 94 | $1,688 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 38 | $648 |
| Ropinirole Hcl | 18 | $639 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $249 | $478,54337 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $102 | $133,315212 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $321 | $22,12438 claims |
| MerckDulera | $14 | $4,01612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 81 pulmonary disease providers in Nebraska.
Other pulmonary disease in Lincoln
- Ryan MartinLincoln$600K
- Douglas FiedlerLincoln$23K
- Kevin ReichmuthLincoln$22K
- William JohnsonLincoln$18K
- Matthew MaslonkaLincoln$14K
- Jakeb RiggleLincoln$13K
- Jonathan SpencerLincoln$9K
- Louis VioliLincoln$6K
- Jeffrey JarrettLincoln$5K
- Sean BarryLincoln$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.